Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e55-8. doi: 10.1016/j.clml.2013.11.010. Epub 2013 Nov 22.

Authors

Marlise R Luskin¹, Darshan B Roy², Mariusz A Wasik², Alison W Loren³

Affiliations

¹ Abramson Cancer Center, Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: [email protected].
² Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
³ Abramson Cancer Center, Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

PMID: 24393621
DOI: 10.1016/j.clml.2013.11.010

No abstract available

Keywords: Epstein-Barr virus; Hyper-CVAD; Immunodeficiency; Lymphoma.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Burkitt Lymphoma / drug therapy*
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Dexamethasone / administration & dosage
Dexamethasone / adverse effects
Doxorubicin / administration & dosage
Doxorubicin / adverse effects
Epstein-Barr Virus Infections / chemically induced
Epstein-Barr Virus Infections / diagnosis*
Epstein-Barr Virus Infections / virology
Female
Herpesvirus 4, Human / physiology
Hodgkin Disease / chemically induced
Hodgkin Disease / diagnosis*
Hodgkin Disease / virology
Host-Pathogen Interactions
Humans
Lymphoma, Large B-Cell, Diffuse / chemically induced
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / virology
Male
Middle Aged
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Time Factors
Vincristine / administration & dosage
Vincristine / adverse effects

Substances

Vincristine
Dexamethasone
Doxorubicin
Cyclophosphamide